1.
Article
| IMSEAR
| ID: sea-223068
2.
3.
Indian J Dermatol Venereol Leprol
;
2019 Mar; 85(2): 226-228
Article
| IMSEAR
| ID: sea-192463
4.
Indian J Dermatol Venereol Leprol
;
2016 Nov-Dec; 82(6): 708-711
Article
in English
| IMSEAR
| ID: sea-178517
5.
An. bras. dermatol
;
91(5): 700-701, Sept.-Oct. 2016. graf
Article
in English
| LILACS
| ID: biblio-827742
6.
An. bras. dermatol
;
91(5): 642-644, Sept.-Oct. 2016. graf
Article
in English
| LILACS
| ID: biblio-827761
ABSTRACT
Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
Subject(s)
Humans , Male , Aged , Skin Neoplasms/drug therapy , Sezary Syndrome/drug therapy , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Skin Neoplasms/blood , Blood Cell Count , Antigens, Differentiation, T-Lymphocyte/metabolism , Sezary Syndrome/blood , Treatment Outcome , Alemtuzumab
7.
Indian J Dermatol Venereol Leprol
;
2016 May-June; 82(3): 356-357
Article
in English
| IMSEAR
| ID: sea-178222
8.
Indian J Dermatol Venereol Leprol
;
2014 Nov-Dec; 80(6): 542-544
Article
in English
| IMSEAR
| ID: sea-154900